Lilly eyes more cancer deals, but wary of CAR-T, gene therapy

Eli Lilly and Co remains in the hunt for cancer drugs even after announcing an $8 billion purchase of Loxo Oncology this week, but it plans to remain on the sidelines when it comes to two of the hottest areas of drug development.

from Reuters: Health News https://reut.rs/2sl6vCf
via IFTTT